NeuroSense Therapeutics (NRSN) Files IPO Registration Statement

NeuroSense Therapeutics (NASDAQ: NRSN) files IPO registration statement. The company intends to offer units, each consisting of one ordinary share and one warrant to purchase one ordinary share.

The company describes itself as: "Our goal is to develop therapeutics to defeat neurodegenerative diseases. We are a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. We believe that these diseases, which include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1 billion. Due to the complexity of neurodegenerative diseases, our strategy is to develop combined therapies targeting multiple pathways associated with these diseases."

Maxim Group LLC will serve as sole underwriter.

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• Kyntra Bio presents roxadustat data showing transfusion improvements in MDS
• ChowChow Cloud addresses unusual trading activity in shares